Member Info for researcher1

say no more.....

seconded MBMW, we already knew what AN would have to say, but his attitude has altered from one slightly baffled by muted market interest, to one confident that this is going to be a blockbuster, easily capable of unlocking all his £4 per share options...

I did the same with Ocado crl123, so understand your viewpoint (although I sold at 70p as it moved up, thankful to get out with a small loss). With Angle I did the reverse, and as stress selling by Jupiter tanked it to 38p a share, just as it submitted for FDA approval, I threw everything I had at it (selling out of everything else except SBTX) and kept adding as it went up to 80p. (currently 135) I plan to do similarly here.

I now have an average of 64 - with a much larger holding than I'm comfortable with (about one-seventh of my portfolio). Who would have thought that possible??

purchased as promised! Consequently I'll raise my recommendation from Buy to Strong Buy!

p.s. the chart looks ready to deliver a hard bounce - any thoughts?

hi all - I sold out here at 1053p, what seems an age ago. OK, I accept that the pandemic is fading, but what is the SP doing down here with the amount of cash they've earned?? Think I may use some of that earlier £45K profit to rebuy today. 2 tranches of £6K I think.

Dibs, I think you will find there is actually a LOT of interest in Angle - will countless posts going back ten or more years. The relatively few number of posts today is because we already know what's afoot!

at last - and with forthcoming SBTX valuation, Opti will be hugely undervalued...

indeed, time is telling.....

Drums, don't fret about it. This first submission is De Novo because it refers to a new device, as well as a specific cancer (MBC). Angle tried a 'broad brush' approach previously, but were advised by the FDA to go away and return with a highly specific submission(s). Once the De Novo is granted, it will mean each cancer type needs to be addressed individually, but Angle can use a streamlined application which is much faster (and much cheaper too - £500K). They will also need the same streamlined process when they want to upgrade the Parsortix machine.

I agree that SP response is underwhelming, but don't blame AN please!

great news for future clinical contracts - as well as, obviously, for patients. I wonder when the market will wake up to the potential? post-FDA I expect....

Almost

yep, heavily - I'll be in profit by Thursday!

ha ha - at least have the courtesy to spell my name right...

you must be fool indeed to have lost money on Angle, sitting at an all time high MCAP and SP

please go tell the people paying you for your nonsense that they are barking up the wrong tree.

ha ha - at least have the courtesy to spell my name right...

you must be fool indeed to have lost money on Angle, sitting at an all time high MCAP and SP

please go tell the people paying you for your nonsense that they are barking up the wrong tree.

I say the 70s crl123 - just checked - actually 78.9 - so only just... bought a lot on Friday and two tranches today

I bought even more out of sheer annoyance this morning when the SP dropped in relation to that RNSR - only an early diagnosis for prostate cancer - not in the least useful.....

yes, DON'T sell Angle Sanji!